Scarica l'app Stockscreener
7.87
7.07%
0.52
Precedente Chiudi:
$7.35
Aprire:
$7.39
Volume 24 ore:
652.56K
Relative Volume:
2.75
Capitalizzazione di mercato:
$134.19M
Reddito:
$137.27M
Utile/perdita netta:
$-123.57M
Rapporto P/E:
-0.7144
EPS:
-11.016
Flusso di cassa netto:
$-102.89M
1 W Prestazione:
+6.93%
1M Prestazione:
+36.87%
6M Prestazione:
+86.05%
1 anno Prestazione:
-31.79%
Intervallo 1D:
$7.39
$8.15
Intervallo di 1 settimana:
$7.01
$8.15
Portata 52W:
$3.51
$11.55
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.87 | 125.32M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - moha.gov.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteMarket Activity Recap & Weekly Return Optimization Plans - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investors2025 Earnings Impact & Fast Gain Stock Tips - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Karyopharm (Nasdaq: KPTI) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - Karyopharm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
[424B3] Karyopharm Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risks2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Why Karyopharm Therapeutics Inc. (25K0) stock trades below fair valueJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
How Karyopharm Therapeutics Inc. stock reacts to job market dataStock Surge & AI Driven Price Predictions - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock undervalued by metrics2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for Karyopharm Therapeutics Inc. stockJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why pension funds invest in Karyopharm Therapeutics Inc. (25K0) stockRate Cut & Technical Pattern Recognition Alerts - newser.com
Can Karyopharm Therapeutics Inc. stock hit record highs againGold Moves & AI Driven Stock Movement Reports - newser.com
Is Karyopharm Therapeutics Inc. stock attractive for long term wealth building2025 Short Interest & Consistent Profit Alerts - newser.com
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):